The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.
The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Intravenous Immunoglobulin Market:
The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Intravenous Immunoglobulin Key Market Segments:
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency Disease
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Specific Antibody Deficiency
Guillain Barre Syndrome
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
Key Players Profiled
Baxter international Inc.
Kedrion Biopharma Inc.
China Biologics Products, Inc.
The other players of the intravenous immunoglobulin market included in the value chain analysis (but not profiled in the report) are as follows:
Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Overview of Immunoglobulin
3.2.1. Patented products
3.2.2. Epidemiology and economic burden of chronic conditions
3.3. Key findings
3.3.1. Top Investment Pockets
3.4. Porters five forces analysis
3.5. Value chain analysis
3.5.1. Primary activities
3.5.2. Support activities
3.6. Market share analysis, 2017
3.7. Product scenario in intravenous immunoglobulin market
3.8. Government regulations and reimbursements
3.9. Indications for immunoglobulin
3.9.1. U.S. FDA indications
3.10. Component analysis of immunoglobulin G (IgG)
3.11. Market dynamics
184.108.40.206. Rise in prevalence of immunodeficiency diseases
220.127.116.11. Increase in adoption of immunoglobulin treatment
18.104.22.168. Growth in incidence of bleeding disorders
22.214.171.124. Stringent government regulations
126.96.36.199. High cost of therapy
188.8.131.52. Opportunities in emerging economies
184.108.40.206. Development of cost-effective therapeutics through large-scale production
CHAPTER 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1.1. Market size and forecast
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Primary immunodeficiency diseases
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. Multifocal motor neuropathy
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. Inflammatory myopathies
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11.1. Market size and forecast
CHAPTER 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
220.127.116.11. Key market trends
5.1.2. Clinical interpretations
18.104.22.168. Key Market Trends
5.1.4. Clinical interpretation
22.214.171.124. Key Market Trends
5.1.6. Clinical interpretation
126.96.36.199. Key Market Trend
5.1.8. Clinical interpretation
188.8.131.52. Key Market Trends
5.1.10. Clinical interpretation
CHAPTER 6: INTRVAENOUS IMMUNOGLOBULIN MARKET, BY REGION
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. North America market size & forecast, by application
6.2.3. North America market size & forecast, by country
184.108.40.206. U.S. market size & forecast
220.127.116.11. Canada market size & forecast
18.104.22.168. Mexico market size & forecast
6.3.1. Key trends and opportunities
6.3.2. Europe market size & forecast, by application
6.3.3. Europe market size & forecast for immunoglobulin market, by country
22.214.171.124. Germany market size & forecast
126.96.36.199. France market size & forecast
188.8.131.52. UK market size & forecast
184.108.40.206. Italy market size & forecast
220.127.116.11. Austria market size & forecast
18.104.22.168. Russia market size & forecast
22.214.171.124. Rest of Europe market size & forecast
6.4.1. Key trends and opportunities
6.4.2. Asia-Pacific market size & forecast, by application
6.4.3. Asia-Pacific market size & forecast, by country
126.96.36.199. Australia market size & forecast
188.8.131.52. China market size & forecast
184.108.40.206. India market size & forecast
220.127.116.11. Japan market size & forecast
18.104.22.168. Rest of Asia-Pacific market size & forecast
6.5.1. Key trends and opportunities
6.5.2. LAMEA market size & forecast, by application
6.5.3. LAMEA market size & forecast, by country
22.214.171.124. Brazil market size & forecast
126.96.36.199. Saudi Arabia market size & forecast
188.8.131.52. Argentina market size & forecast
184.108.40.206. Turkey market size & forecast
220.127.116.11. Rest of LAMEA market size & forecast
CHAPTER 7: COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BAYER AG
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. BIOTEST AG
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. CHINA BIOLOGIC PRODUCTS, INC.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. CSL LIMITED
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. GRIFOLS S.A.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. KEDRION BIOPHARMA INC.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. LFB SA (LFB BIOTECHNOLOGIES SAS)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. OCTAPHARMA AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
*Full List of Tables and Figures Available on Enquiry.
Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds its application in various fields, including hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, & hypogammaglobulinemia; increase in immunoglobulin indications; improved production & purification processes; growth in awareness toward antibody deficiency; and rare immune disorders among patient population drive the growth of the global intravenous immunoglobulin market.
Based on application segment, hypogammaglobulinemia held the largest market share in 2017, and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.
Key Findings of the Intravenous Immunoglobulin (IVIG) Market:
Myasthenia gravis segment is projected to grow at the highest rate during the forecast period.
Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period.
North America dominated the global intravenous immunoglobulin market in 2017.
LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025.
In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities.
The key companies profiled in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer AG. The other players included in the value chain analysis (but not included in the report) are Omrix Biopharmaceuticals Ltd.; Behring GmbH; Shanghai RAAS Blood Products Co., Ltd.; Option Care Enterprises, Inc.; ADMA Biologics, Inc.; and BioScrip, Inc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.